Perampanel in Patients with a History of Psychiatric Illness: Post Hoc Analysis of Four Randomized Phase III Studies (304, 305, 306, and 335) and their Open-Label Extensions (307 and 335 OLEx)

被引：0
|
作者：
Kanner, Andres M. [1 ]
Patten, Anna [2 ]
Malhotra, Manoj [3 ]
机构：
[1] Univ Miami, Miller Sch Med, Miami, FL 33136 USA
[2] Eisai Ltd, Hatfield, Herts, England
[3] Eisai Inc, Woodcliff Lake, NJ USA
来源：
NEUROLOGY | 2020年 / 94卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
1850
引用
收藏
页数：3
相关论文
共 35 条
  • [31] Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus®): a Post Hoc Analysis of a Randomized, Open-Label, Phase 3 Trial
    Yan, Xiang
    Feng, Chen
    Lou, Ying
    Zhou, Zhiguang
    DIABETES THERAPY, 2022, 13 (06) : 1161 - 1174
  • [32] Predictors of improvements in patient-reported endpoints: Post-hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria (PNH)
    Schrezenmeier, H.
    Kulasekararaj, A.
    Mitchell, L.
    de Latour, Peffault R.
    Devos, T.
    Okamoto, S.
    Wells, R.
    Johnston, K.
    Popoff, E.
    Cheung, A.
    Gustovic, P.
    Wang, A.
    Wang, J.
    Tomazos, I.
    Patel, Y.
    Lee, J. W.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 235 - 236
  • [33] Predictors for Improvement in Patient-Reported Outcomes: Post-Hoc Analysis of a Phase 3 Randomized, Open-Label Study of Eculizumab and Ravulizumab in Complement Inhibitor-Naive Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Schrezenmeier, Hubert
    Kulasekararaj, Austin G.
    Mitchelli, Lindsay
    De Latour, Regis Peffault
    Devos, Timothy
    Okamoto, Shinichiro
    Wells, Richard
    Johnston, Karissa
    Popoff, Evan
    Cheung, Antoinette
    Wang, Jimmy
    Gustovic, Philippe
    Wang, Alice
    Tomazoz, Ioannis
    Patel, Yogesh
    Lee, Jong Wook
    BLOOD, 2021, 138
  • [34] Lipid profile with eslicarbazepine acetate and carbamazepine monotherapy in adult patients with newly diagnosed focal-onset seizures: Post-hoc analysis from a phase III, randomized, double-blind study and a 2-year open-label extension ESL study
    Trinka, Eugen
    Rocamora, Rodrigo
    Moreira, Joana
    Pereira, Ana
    Fonseca, Miguel
    Fernandez, Guillermo Castilla
    Ikedo, Fabio
    NEUROLOGY, 2021, 96 (15)
  • [35] Lower injection-site reactions and long-term safety, immunogenicity, and efficacy of etanercept biosimilar YLB113: Results from a post-hoc analysis of a double-blind, randomized, phase III comparative study and its open-label extension in patients with rheumatoid arthritis
    Yamanaka, Hisashi
    Tanaka, Yoshiya
    Hibino, Toshihiko
    Unmesh, Gopalakrishnan
    Shah, Chirag
    Bakhle, Dhananjay
    Stefanidis, Dimitris
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2023, 26 (01) : 108 - 115
1234